Perrigo announces summertime availability of desloratadine in Rx and OTC

Perrigo allows for possiblity that Clarinex may switch to nonprescription status in next six months

ALLEGAN, Mich. — Perrigo last week announced that it has received final Food and Drug Administration approval for its generic prescription allergy remedy desloratadine 5 mg, the generic equivalent to Schering-Plough's Clarinex.

Under the terms of a patent-infringement suit settlement, Perrigo can commercially launch its generic desloratadine product July 1. The new product launch may be a prescription or over-the-counter product, depending on its status at the time of launch, Perrigo stated.

Clarinex sales were approximately $185 million, according to Perrigo, citing Wolters Kluwer data.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.